Browse the evidence

Obesity and Obstructive Sleep Apnea (OSA) exacerbate the risk of AF in MASLD through hemodynamic changes, epicardial fat deposition, and sympathetic nervous system activation.

For MASLD patients, managing weight and treating sleep apnea are critical for preventing AF. These conditions add mechanical and inflammatory stress to the heart, which can be mitigated through lifestyle and medical interventions.

Thyroid hormone substitution therapy in hypothyroid patients produces only modest weight loss (3-5 kg) and does not resolve obesity; therefore, obesity treatment should not be delayed until thyroid levels are normalized.

Do not wait for your thyroid levels to normalize before starting weight loss efforts. Thyroid medication will only help you lose a small amount of weight (3-5 kg). Focus on behavioral changes (diet and exercise) and other obesity treatments immediately, as these are the primary drivers of weight loss.

Twice-per-week intermittent fasting (5:2 diet) is not superior to continuous energy restriction for weight loss or insulin resistance in night shift workers, though it may offer specific lipid benefits.

For night shift workers, a 5:2 intermittent fasting plan (eating ~500 kcal on 2 non-consecutive days) is just as effective for weight loss as eating slightly less every day. It does not offer superior metabolic benefits like insulin sensitivity, but it may help lower LDL cholesterol. Choose the method that fits your schedule best, as adherence is key.

A 12-month 4:3 intermittent fasting protocol does not produce different changes in fasting appetite-related hormones (leptin, ghrelin, PYY, BDNF, adiponectin) compared to daily caloric restriction when energy deficits are matched.

Don't expect intermittent fasting to magically fix your hunger hormones differently than daily calorie counting. The benefit of 4:3 IMF comes from how it changes your eating behaviors and psychological relationship with food, not from a unique hormonal advantage.

Time-restricted eating (TRE) does not significantly improve BMI, fat mass, blood lipids, glucose, or blood pressure in overweight and obese women compared to control groups.

Do not expect TRE to automatically fix your BMI or cholesterol levels if you do not also manage your total calorie intake. While it helps with weight and insulin, it does not significantly alter fat mass or blood pressure on its own in this population.

Combining Time-Restricted Eating (TRE) with Energy Restriction (ER) provides no additional benefit for weight loss or fat mass reduction compared to TRE alone.

If you are already practicing Time-Restricted Eating, you do not need to add explicit calorie counting or energy restriction to achieve weight loss. TRE alone is sufficient for significant fat and weight reduction. Adding calorie restriction does not provide extra benefits for weight loss in this context.

Peri-operative protein or amino acid supplementation does not significantly improve muscle strength (quadriceps or handgrip) or functional outcomes in total joint arthroplasty patients.

Do not expect protein supplements to restore your leg strength after surgery. The evidence shows they help keep muscle mass from shrinking, but they do not significantly improve strength or walking ability on their own. You must combine supplementation with physical therapy and exercise to regain strength.

Traditional weight management strategies, including lifestyle interventions and metabolic and bariatric surgery (MBS), are generally ineffective for reducing hyperphagia in patients with rare MC4R pathway diseases because they do not address the underlying pathophysiology.

For patients with rare genetic obesity (POMC, LEPR, BBS, etc.), standard diets, exercise programs, and even weight-loss surgery often fail to control the insatiable hunger (hyperphagia). This is not a failure of willpower but a failure of the treatment to address the specific brain signaling defect. Recognizing this can reduce caregiver guilt and shift focus toward seeking targeted genetic therapies.

Reducing global obesity prevalence to 2019 levels could save an estimated US$2.2 trillion annually by 2060 through healthcare and productivity-related cost savings.

Addressing obesity at a population level saves massive amounts of money globally. Public health policies that reduce obesity prevalence have a high economic return on investment.

Other GLP-1 receptor agonists and SGLT2 inhibitors, including semaglutide, dulaglutide, and canagliflozin, did not demonstrate a statistically significant elevation in gynecologic tumor risk compared to controls.

If you are taking other GLP-1 receptor agonists (like semaglutide or dulaglutide) or SGLT2 inhibitors (like canagliflozin or empagliflozin), this network meta-analysis did not find a statistically significant increase in gynecologic tumor risk for these agents. However, the authors note that more data is needed to confirm whether the association with tirzepatide is causal.

GLP-1 receptor agonists (GLP-1 RAs) are not cost-effective at current prices, requiring significant price reductions to meet standard willingness-to-pay thresholds.

GLP-1 RAs are clinically effective but not cost-effective at current prices. They should be used selectively (e.g., for those who cannot undergo surgery) and only if pricing aligns with their health benefits.

Peripheral GLP-1 signaling is not essential for long-term energy balance or bodyweight regulation in humans or rodents, as evidenced by normal body weight in GLP-1R knockout mice and lack of effect from peripheral antagonism.

Your body's natural production of GLP-1 in the gut does not significantly control your long-term weight. This is why lifestyle changes alone often fail to sustain weight loss, and why pharmacologic doses that strongly activate brain receptors are needed for significant weight reduction.

GLP-1 receptor internalization is arrestin-independent and relies on a dual mechanism involving Gs/Gi/o protein activation, GRK phosphorylation, and both clathrin- and caveolae-mediated endocytosis.

This research clarifies that GLP-1 drugs work by engaging specific cellular recycling pathways (clathrin and caveolae) rather than the arrestin pathway. This mechanistic insight aids in designing drugs with optimized duration and fewer side effects, though it does not change immediate patient behavior.

Public awareness of the clinical success of anti-obesity medications (AOMs) does not reduce obesity stigma or shift public perception of obesity from a failure of willpower to a biological medical condition.

Health communicators and policymakers should not assume that highlighting the success of GLP-1 medications will automatically reduce obesity stigma. Since stigma is robustly linked to personal weight loss experiences and willpower beliefs, interventions must directly address these cognitive biases rather than relying on medical awareness alone.

Circulating IGF-1 concentrations are not associated with all-cause, cardiovascular disease, or cancer-related mortality risk.

There is no evidence from this study that your natural IGF-1 levels predict your risk of death from cancer, heart disease, or other causes. You do not need to try to manipulate IGF-1 levels for longevity based on this data.

Loss-of-function mutations in the myostatin (MSTN) gene cause excessive skeletal muscle growth (hypertrophy) and increased strength by removing the natural inhibition on muscle development.

This paper describes a rare genetic condition (myostatin deficiency) that causes massive muscle growth. For the average person, this is not a viable or safe intervention. However, understanding that myostatin limits growth suggests that therapies blocking it (under medical supervision) might help those with muscle-wasting diseases, but it is not a recommendation for healthy individuals seeking hypertrophy.

Semaglutide does not significantly impact renal outcomes, including nephrolithiasis, acute kidney injury, or chronic kidney disease, in patients with overweight or obesity.

If you are using semaglutide for weight management or cardiovascular risk reduction, do not expect it to protect your kidneys. This meta-analysis found no significant impact on renal outcomes like kidney stones or acute kidney injury in overweight or obese patients.

Pharmacological inhibition of Complement C3 using AMY-101 improves healthspan, metabolic fitness, and reduces inflammaging in aged mice.

In aged mice, weekly injections of a C3 inhibitor (AMY-101) improved metabolic health and physical function. This suggests that targeting the complement system could be a viable strategy to combat age-related decline, potentially mimicking the benefits of caloric restriction.

Age-associated elevation of C3a in visceral adipose tissue (VAT) is primarily driven by adipose tissue macrophages (ATMs) via an autocrine ERK-dependent signaling loop.

In aging, fat tissue (specifically visceral fat) becomes a source of inflammation due to immune cells (macrophages) producing complement proteins like C3a. This process is driven by specific signaling pathways within these cells.

Obesity heritability is estimated at 40-70%, driven by over 1000 genetic variants and complex interactions with environmental and epigenetic factors, with early-onset severe obesity strongly linked to specific genetic mutations.

Recognize that obesity has a strong biological basis, with heritability estimates up to 70%. For those with early-onset severe obesity, genetic factors play a major role. This understanding supports the use of targeted therapies and early screening rather than relying solely on lifestyle advice.

Chronic hyperglycemia and oxidative stress induce beta-cell dedifferentiation by altering the balance of PAX4 and ARX gene expression, causing beta-cells to lose insulin-secreting identity and adopt alpha-cell features.

In Type 2 Diabetes, high blood sugar and stress can cause insulin-producing beta-cells to 'forget' their job and turn into glucagon-producing alpha-like cells. This is driven by epigenetic changes to genes like PAX4 and ARX. This loss of identity contributes to worsening blood sugar control, suggesting that therapies aiming to restore beta-cell identity or function could be beneficial.

Tirzepatide attenuates alcohol-induced dopamine release in the nucleus accumbens and induces sustained synaptic depression in the lateral septum.

Tirzepatide's effect on alcohol reward involves reducing dopamine release in the nucleus accumbens and altering synaptic plasticity in the lateral septum.

Bariatric surgery in older adults (≥65 years) is associated with significantly higher rates of in-hospital mortality and complications compared to younger adults, and should be reserved for refractory cases.

Surgery is the most effective weight loss method but carries higher risks for those over 65. It should only be considered if you have severe obesity and have failed all other treatments, after a thorough risk-benefit discussion with specialists.

Genetically predicted higher childhood obesity, adult obesity, and increased fat-free mass are causally associated with a reduced risk of Brugada syndrome.

If you have Brugada syndrome, maintaining a BMI in the upper-normal range and increasing fat-free mass through resistance training may help reduce your risk. This contrasts with general population advice to lose weight, so consult your cardiologist about personalized weight management.